Security
Clinuvel Pharmaceuticals Ltd Sponsored ADR (Australia) · CLVLY
CLVLYOTCotherHistorical · closed Jul 20, 2026CIK 1290877Updated Nov 2, 2026
CLVLY price & chart
This listing closed Jul 20, 2026. Live provider charts are shown only for current listings.
Current security: CLVLF
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Filing attachments
ex99-1.htm · 6-K · 2026-10-30
Exhibit 99.1 ASX ANNOUNkhCEMENT ASX : CUV | Nasdaq : CUVL | Börse Frankfurt: UR9 CLINUVEL files NEURACTHEL ® Instant dossier Submission of ACTH product to first European regulatory agencies Executive Summary CLINUVEL files NEURACTHEL® Instant through decentralised procedure in Europe Branded generic formulation of tetracosactide, synthetic peptide analogue of natural ACTH First national regulator reviews in three EU counties based on commercial priorities DCP requires 300 d…
Read attachment ↗ex99-1.htm · 6-K · 2026-10-01
Exhibit 99.1 SCENESSE® response in vitiligo: new cases from the CUV105 trial presented to EADV Melbourne / Singapore - 1 October 2026 - CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced that new patient cases demonstrating the clinical response to SCENESSE® (afamelanotide) with adjunct narrowband ultraviolet B (NB-UVB) phototherapy in vitiligo patients are being presented to the European Academy of Dermatology and Venerology (EADV) conference in Vienna. Treatment effect i…
Read attachment ↗